Change Notification (25 JOD): Which Changes Must Be Reported to the JFDA

1. Key takeaways

The JFDA fee schedule prices the change study at 25 JOD, the lowest of the nine fees. GRZAN’s conclusion is that a low fee does not mean low importance — an unreported change will surface simultaneously at three points: renewal, market surveillance and import approval. The asymmetry between a 25 JOD fee and the cost of an exposed non-compliance is the central economic argument for filing on time.

• Second conclusion: the changes that must be reported include major changes in three categories — the device itself, the manufacturing process, and the quality system. The specific handling depends on the nature of the change: it may require a supplementary filing, or it may require re-registration. The decision between the two routes should be made before documents are prepared.
• Third conclusion: certificate updates also go through the variation channel. After a manufacturer’s CE certificate, FDA approval or ISO certificate is renewed or reissued, the updated copies should be provided to the JFDA through the AR. The updated copies should reach the AR as soon as they are issued, so that the filing can be prepared without delay.

2. Legal basis

The change notification obligation and its fee rest on the following instruments. The fee schedule entry is included because the change study fee applies to every variation filing, whatever the category of the change.

Clause numbers must be verified against the Arabic originals published in the Official Gazette of Jordan and issued by the JFDA; the amounts are the official fees listed in the JFDA fee schedule.

3. Expert insights

Insight 1: a three-way taxonomy of change — device, process and system. Device changes cover design, materials, intended use, labelling and the instructions for use; process changes cover the manufacturing flow, the sterilisation method and the production site; system changes cover the certification status of the quality management system and the holder information of the certificates. The three categories differ in the depth of assessment they receive. The taxonomy also shapes the internal workflow: the three categories are owned by different functions in the manufacturer, so the assessment process needs input from engineering, manufacturing and quality. Labelling the categories at the moment of change keeps the later filing discussion short.

Insight 2: certificate updates are the highest-frequency scenario for change filings. ISO 13485 is re-evaluated every three years, CE certificates carry validity periods, and FSCs need to be reissued — each of these produces a duty to submit updated copies. The single fee of 25 JOD is small, but the frequency of filing is high. The practical consequence is administrative: a manufacturer holding several certificates should expect a steady stream of small filings rather than occasional large ones. Budgeting a small annual envelope for these filings is more accurate than budgeting per event.

Insight 3: a change can escalate into re-registration. Where a change amounts to an essential alteration of the product — for example a change of intended use or a change of classification level — the JFDA may require re-registration (circulation study 700 JOD) rather than a variation filing. Companies should judge the nature of a change before assessing how to handle it. The boundary matters because the two routes differ in fee, in timeline and in review depth.

Insight 4: unreported changes have three exposure paths. They are discovered in the document comparison at renewal; they are discovered in label checks during market surveillance; and they are discovered in performance comparison during batch testing. Exposure through any one of the three paths creates a record of compliance deficiency. Because the three paths are independent, an unfiled change can be discovered even years after it was made.

Insight 5: change filings must be completed through the AR. As with all Jordanian procedures, the variation filing is submitted by the AR through its account in the JFDA system. The agreement should stipulate the AR’s cooperation deadlines. The AR is thus the practical gatekeeper of change compliance, and its responsiveness is part of the manufacturer’s own compliance posture.

4. Practical recommendations

• Establish a change impact assessment process. Before any design, process, system or certificate change takes effect, assess first whether it triggers a filing obligation in Jordan. The assessment should be recorded, so that the judgement is auditable later.
• Put certificate updates into a change filing calendar. Every update of ISO 13485, CE, FDA or FSC should correspond to one variation filing (25 JOD). The calendar should be owned by the same function that owns the change process.
• Agree the AR’s cooperation deadlines for change filings in the agreement, so that delays caused by the AR do not leave changes pending. The deadline should be measured from the moment the manufacturer notifies the AR.
• Judge whether a change escalates into re-registration. For changes touching the intended use or the classification, plan the timeline on the basis of re-registration (700 JOD). The extra timeline of re-registration should be reflected in the launch plan.

5. Verification checklist

• □ A change impact assessment process is in place (device, process and system categories)
• □ Updates of ISO 13485, CE, FDA and FSC have been entered into the change filing calendar
• □ Whether changes escalate into re-registration (700 JOD) has been assessed
• □ The AR’s cooperation deadline for change filings has been agreed in the agreement
• □ The variation filing fee of 25 JOD has been included in the budget
• □ It has been checked whether any changes in past periods remain unfiled
• □ The cited clause numbers have been re-verified against the Arabic originals of the Official Gazette

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Jordanian market. Our team coordinates local importer arrangements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com